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Abstract Anemia is common in chronic renal failure.
Guidelines for the diagnosis and treatment of anemia in
adult patients are available. With respect to the diagnosis
and treatment in children on peritoneal dialysis, the Eu-
ropean Pediatric Peritoneal Dialysis Working Group
(EPPWG) has produced guidelines. After a thorough 
diagnostic work-up, treatment should aim for a target 
hemoglobin concentration of at least 11 g/l. This can be
accomplished by the administration of erythropoietin and
iron preparations. Although there is sufficient evidence
to advocate the intraperitoneal administration of erythro-
poietin, most pediatric nephrologists still apply erythro-
poietin by the subcutaneous route. Iron should preferably
be prescribed as an oral preparation. Sufficient attention
has to be paid to the nutritional intake in these children.
There is no place for carnitine supplementation in the
treatment of anemia in pediatric peritoneal dialysis pa-
tients.
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The treatment of anemia in chronic kidney disease has
been summarized in the NKF/DOQI guidelines [1],
which have recently been updated [2]. European best
practice guidelines have also been recently published
[3]. These published guidelines pay no, or very limited,
attention to the special situation in children.
The European Pediatric Peritoneal Dialysis Working
Group (EPPWG) was established in 1999 by pediatric
nephrologists with a major interest in peritoneal dialysis
and has, among other things, published guidelines on
commencing elective chronic peritoneal dialysis [4]. One
of the functions of the group is to establish expert guid-
ance in important clinical areas associated with peritone-
al dialysis in conjunction with other members of the
multidisciplinary team. These guidelines were initiated
and discussed at meetings of the group and developed by
e-mail discussion to develop a consensus of opinion
based upon cumulative clinical experience and reported
studies. The present guidelines apply to the management
of anemia in pediatric peritoneal dialysis patients.
Definition of anemia
More than in adult patients, hemoglobin and hematocrit
values are age dependent in children [5], (Tables 1, 2, 3,
4). Also, concentrations of ferritin, transferrin, and iron
are dependent on age. Early iron deficiency may be diag-
nosed by an increase in hypochromic red blood cells [6].
The technique for measuring this parameter is not avail-
able everywhere. Since children with renal failure gener-
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Table 1 Reference ranges of anemia parameters in children [5]:
hemoglobin and hematocrit (M male; F female)
Hemoglobin (g/dl) Hematocrit (%)
1–3 days 14.5–22.5 45–70
2 months 9.0–14.0 28–42
6–12 years 11.5–15.5 35–45
12–18 years, M 13.0–16.0 37–49
F 12.0–16.0 36–46ally do not have underlying co-morbidity contributing to
anemia, it is obvious that in children on peritoneal dialy-
sis normal hematocrit levels should be aimed for (opin-
ion). The work-up of the anemic child is not different
from the work-up that is advocated for adult patients by
the DOQI guidelines, although the importance of a stool
test for occult blood may be less useful in this age group
[2, 7] (opinion):
– Iron deficiency
– Clinical history
– Assessment of nutritional status
– Hemoglobin and hematocrit
– Red blood cell indices
– Reticulocyte count
– Iron parameters
– Serum iron
After this work-up has been completed, iron and/or
erythropoietin therapy should be initiated to obtain a tar-
get hemoglobin concentration of at least 11 g/dl (hemat-
ocrit 33%), although there is a tendency to increase this
target [8] (opinion).
A target hemoglobin concentration of at least 11 g/l
should be aimed for in children on peritoneal dialysis
(opinion).
Erythropoietin
Most experience has been obtained with subcutaneous
administration of recombinant human erythropoietin [9,
10]. Erythropoietin is available as erythropoietin alpha
and beta. Erythropoietin alpha and beta differ noticeably
in their formulation excipients. No clear prescription
schedules for starting erythropoietin are available for
children, and schedules provided in the literature vary
greatly. It seems reasonable to start with a subcutaneous
dosage of 50–100 U/kg body weight 2 or 3 times per
week. In some selected patients (particularly if started in
the predialysis period) a lower frequency or dosage can
be attempted. In studies in adult patients once weekly
subcutaneous administration of erythropoietin was effec-
tive for the treatment of renal anemia [11, 12, 13]. It is
well known that younger children need relatively more
erythropoietin than older ones [14] (evidence). Mainte-
nance recommendations vary from 300 U/kg/week for a
child with a weight of <20 kg to 120 U/kg/week for a
child with a weight of >30 kg [10] (opinion). Each child
will need the dosage titrated to achieve the target hemo-
globin concentrations. For the titration of erythropoietin
the DOQI guidelines can be used [2]. If the increase in
hematocrit after initiation of erythropoietin therapy is
less than 2% over a 2- to 4-week period, the dose should
be increased by 50%. If the absolute rate of increase in
hematocrit after initiation of erythropoietin therapy or af-
ter a dose increase exceeds 8% per month, the weekly
dose of erythropoietin should be decreased by 25%.
Side effects of erythropoietin therapy are rare; in-
creased clotting tendency, hypertension, and seizures are
to be considered the consequence of the therapeutic 
effect rather than an adverse effect of the preparation.
Nevertheless, blood pressure should be carefully moni-
tored during therapy.
Recently, attention was drawn to a severe side effect
of erythropoietin therapy, pure red blood cell aplasia due
to the occurrence of neutralizing antierythropoietin anti-
bodies [15, 16]. Subsequent investigations showed that
this was in most cases associated with subcutaneously
administered erythropoietin alpha from one brand, al-
though some cases have also been described using the
other brand available on the market. The application of
erythropoietin beta is associated with a much lower inci-
dence of this severe side effect. In many countries the
subcutaneous administration of erythropoietin alpha is
discouraged at present. The administration of darbepoe-
tin alpha is not associated with pure red blood cell apla-
sia, but it should be remembered that experience with
this drug is still limited.
Subcutaneous administration of drugs is psychologi-
cally distressing, especially for children (opinion). The
use of ultrafine needles and special injection pens may
help to alleviate the upset. In adult peritoneal dialysis pa-
tients a noncompliance with erythropoietin administra-
tion was reported in between 35% and 55% of patients
[17, 18]. For children no data on erythropoietin are avail-
able, but from clinical practice it is known that subcuta-
neous administration is frightening and a source of con-
flict between child and caregivers. Limited data are
available on the compliance with another drug which has
to be administered subcutaneously, recombinant human
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Table 2 Reference ranges of anemia parameters in children [5]:
ferritin
Ferritin (ng/ml)
Newborn 25–200
1 month 200–600
2–5 months 50–200
6 months–15 years 7–140
Table 3 Reference ranges of anemia parameters in children [5]:
iron (M male; F female)
Iron (µg/dl)
0–2 months 100–250
2–12 months 40–100
1–12 years 50–120
Thereafter, M 50–160
F 40–150
Table 4 Reference ranges of anemia parameters in children [5]:
transferrin
Transferrin (mg/dl)
Newborn 130–275
Adult 200–400growth hormone. Noncompliance was reported to be be-
tween 50% and 91% [19, 20, 21]. In one study it was re-
ported that noncompliance increased significantly from
41% at 1 year to 91% at 2 years [21]. Intravenous admin-
istration is a more expensive alternative, but will rarely
be applied in pediatric peritoneal dialysis patients [22].
Despite some initial discouraging but still frequently
cited reports in the literature, erythropoietin can be ad-
ministered very well by the intraperitoneal route [23,
24]. If erythropoietin is administered in a small volume
of dialysis fluid (50-ml bags are commercially avail-
able), bioavailability is similar to that after subcutaneous
administration of the same amount of hormone [25] (evi-
dence). Mean dosage needed for maintaining the target
hematocrit decreased from 279 to 194 U/kg/week if the
drug was administered in a 50-ml dialysis bag during the
daytime [26, 27]. In a more recent study in 20 patients
on nightly intermittent peritoneal dialysis mean dosage
was 179 U/kg/week [28]. Dialysis adequacy is a major
factor of concern in such a regimen: KT/V urea was ≥2.2
in the group studied. However, in some patients the ap-
plication of intraperitoneal erythropoietin may be limited
by the inability to obtain adequate dialysis (opinion). In
patients not achieving adequate dialysis, the daytime pe-
riod should be used for additional dialysis exchanges. In
this category, that period will not be available for intra-
peritoneal erythropoietin therapy. Peritonitis frequency
does not need to increase using intraperitoneal erythro-
poietin: the two pediatric studies reporting peritonitis
rates mention one episode every 14.7 and 11.2 treatment
months, respectively [19, 21]. One early study in chil-
dren was broken off because of a high peritonitis rate
[29]; possibly this was due to insufficient training of the
caregivers.
Recently, an erythropoietin analogue was developed
(darbepoetin alpha or NESP = novel erythropoiesis stim-
ulating protein), which is a hyperglycosylated erythro-
poiesis-stimulating protein with a presumed threefold
longer half-life than erythropoietin in man [30, 31, 32,
33, 34] (evidence). In children a two- to fourfold longer
half-life was reported [35]. The pharmacokinetics when
administered intravenously and subcutaneously appear to
be the same in adult and pediatric patients. A random-
ized comparative study of darbepoetin and erythropoietin
in pediatric patients with chronic or end-stage renal dis-
ease is just starting. There are no data available with 
respect to the intraperitoneal administration of darbe-
poetin.
The development of an orally active agonist of the
erythropoietin receptor will be an interesting future fea-
ture [36].
Erythropoietin resistance may be due to a number of
causes:
– Infection
– Hyperparathyroidism
– Malnutrition
– Hemolytic disorders
– Folate or vitamin B12 deficiency
– Underdialysis
– Vitamin C deficiency
– ACE inhibitors
– Anti-erythropoietin antibodies
Since there is an excellent review of these in the adult
guidelines [2, 3, 37], and they are not essentially differ-
ent in children, they are not discussed in detail here. In
children responding poorly to erythropoietin therapy,
special emphasis should be put on the possible contribu-
tion of inflammation or hyperparathyroidism [38]. The
possible occurrence of pure red cell aplasia due to the
development of neutralizing antierythropoietin antibod-
ies has been discussed before.
Erythropoietin should be administered by the subcuta-
neous or intraperitoneal route in children on peritoneal
dialysis (evidence). Although there is sufficient evidence
to advocate the intraperitoneal administration of erythro-
poietin, most pediatric nephrologists still apply erythro-
poietin by the subcutaneous route in their peritoneal dial-
ysis patients.
Iron
Iron supplementation is indicated in virtually all pediat-
ric patients with renal anemia who are treated with eryth-
ropoietin. According to the DOQI guidelines, transferrin
saturation should be maintained above 20% and serum
ferritin concentration above 100 ng/ml [2] (evidence).
There is no reason to anticipate that these guidelines
should be different for children and for adults (opinion).
It may be difficult to maintain sufficient iron stores in
children on peritoneal dialysis, using oral iron prepara-
tions only. Iron supplements should be given to prevent
iron deficiency and to maintain adequate iron stores. A
dosage of 2–3 mg/kg body weight per day is recom-
mended and administered in two to three divided doses
either 1 or 2 h after food.
Iron supplements should not be added to the infant
formula or nutrition supplements [39] (evidence). If pos-
sible, they should be prescribed with vitamin C to en-
hance absorption (opinion). However, it is important not
to oversupplement with vitamin C for risk of increased
oxalate formation. Iron supplements should ideally not
be taken with cereals and legumes, tannins (tea, cocoa,
chocolate) and dairy products as these interfere with ab-
sorption. Micronutrient supplements should also be pre-
scribed following individualized dietary assessment and
should account for the potential peritoneal dialysis losses
of folic acid and vitamins C and B6. Compliance with
oral iron preparations for micronutrient supplements may
be difficult and must be reinforced by both medical and
dietetic staff [39, 40].
Parenteral iron preparations, commonly used in pa-
tients on hemodialysis, are more difficult to apply in
children on peritoneal dialysis. After the recent approval
of iron gluconate, iron sucrose, and iron saccharate, the
application of iron dextran should also be abandoned in
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the United States [41, 42, 43, 44] (evidence). Recom-
mended dosage is 2 mg iron per kg per week for intrave-
nous iron sucrose treatment [7]. Before starting intrave-
nous therapy the administration of a test dosis is recom-
mended. It is clear, however, that the intravenous admin-
istration of iron preparations is cumbersome, and oral
administration is preferred [39] (opinion). In rare cases,
for example with noncompliance with oral medication,
intermittent intravenous administration will be indicated.
Limited but positive experience has been obtained
with the intraperitoneal administration of iron dextran,
both in rats and men [45, 46, 47]. Reports on the intra-
peritoneal administration of iron gluconate or iron su-
crose are lacking.
Iron should preferably be prescribed as an oral prepa-
ration (evidence). In rare cases intermittent intravenous
administration will be indicated.
Carnitine
Several studies in adult patients suggest that intravenous
supplementation with L-carnitine reduces requirements
for erythropoietin by 38–50% [48, 49, 50] (opinion).
Published data on the effect of L-carnitine supplementa-
tion on the treatment of anemia in children are very
scarce. One study showed an increase in the hematocrit
by 34% in two children on hemodialysis with L-carnitine
supplementation without modification of erythropoietin
dosage [51]. Another study in 16 children on dialysis, of
whom five were on peritoneal dialysis, showed no bene-
ficial effect of oral supplementation with L-carnitine on
erythropoietin requirement [52].
There is no precise place for carnitine supplementa-
tion in the treatment of anemia in pediatric peritoneal di-
alysis patients (opinion).
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